Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru – 560076, India
T: +91 80 6784 0738

Registered Office:
Cyber One, Unit No. 902, Sector 30A
Plot No - 4 & 6, Vashi, Navi Mumbai
400703 India
F: +91 22 2789 2924
T: 91 22 2789 2942

Date: November 11, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 **Scrip Code: 544292**	**National Stock Exchange of India Ltd** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 **Symbol: ONESOURCE**

Dear Madam/ Sir,

Sub: Press Release:

Please find enclosed herewith Press Release issued by the Company titled:

OneSource reports Q2FY26 performance with revenue growth of 12% and margin expansion of 506 bps YoY.

Board Meeting commenced at 16:10 hrs IST and concluded at 16:35 hrs IST.

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A Digitally signed by Trisha A Date: 2025.11.11 21:07:27 +05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Encl. as above

OneSource reports Q2FY26 performance with revenue growth of 12% and margin expansion of 506 bps YoY

Q2FY26 Performance Highlights

- Revenues at ₹3,758 million, up 12% YoY
- EBITDA grew 37% YoY to ₹1,065 million
- EBITDA margin of 28%, an expansion of ~506 bps YoY
- Adjusted PAT stood at ₹449 million with adjusted EPS of ₹3.9

Kochi, India, November 11, 2025 - OneSource Speciality Pharma Limited *(BSE:544292, NSE: ONESOURCE)* today announced its consolidated financial results for the quarter ended September 30, 2025 (Q2FY26).

Financial Highlights (In ₹ million)

Particulars	Q2FY26	QoQ%	YoY%	H1FY26	YoY%
Revenues	3,758	+15%	+12%	7,030	+12%
EBITDA	1,065	+20%	+37%	1,950	+37%
EBITDA %	28%	~130 bps	~ 506 bps	28%	~ 504 bps
Adjusted PAT[1]	449	+21%	Loss to profit	820	Loss to profit[2]
Adjusted EPS (₹)[1]	3.9	+21%	-	7.2	-

1. *Adjusted PAT and Adjusted EPS excludes exceptional items (Q2FY26: Nil, Q1FY26: ₹29m, Q2FY25: ₹58m) and scheme related intangible amortisation (FY26: ₹344m for each quarter, Q2FY25: ₹357m)*
2. *Excludes one-time tax asset recognised (Q1FY25: ₹411m) as a results of the scheme of arrangement.*

The recently announced proposed acquisition of Poland and Brooks delivered a strong first half with a combined revenue of $29 million and EBITDA of $11 million, translating into healthy margins of 38%.

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, *"Q2 performance was underpinned by MSAs executions and sales from our IP led base business. DDC capacity addition is being accelerated to support upcoming customer launches. We are excited about recently approved proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India and accordingly are raising our FY28 revenue outlook to $500m+."*

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,400 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

Institutional Investors	**Corporate Communication**
Anurag Bhagania CFO **Tejaswani Fotedar** +91 9004331391 Email: investor-relations@onesourcecdmo.com	**Pallavi Panchmatia:** +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com **Abhilash Mukherjee:** +91 89044 28907 Email: abhilash,mukherjee@onesourcecdmo.com **Harsh Sheth**: +91 9870631557 Email: harsh.sheth@mslgroup.com